Eficacia y seguridad de ustekinumab para el tratamiendo en pacientes adultos con enfermedad de Crohn activa moderada a severa, sin respuesta clínica favorable a tratamiento sistémico convencional ni a inhibidores del TNF-ALFA (infliximab y adalimumab), con respuesta favorable a ustekinumab en fase de inducción / Efficacy and safety of ustekinumab for the treatment of adult patients with moderate to severe active Crohn's disease, without favorable clinical response to conventional systemic treatment or TNF-ALFA inhibitors (infliximab and adalimumab), with favorable response to ustekinumab in the induction phase
Lima; IETSI; ago. 2023.
Non-conventional
in Spanish
| BRISA/RedTESA
| ID: biblio-1553020
Responsible library:
BR1.1
Subject(s)
Full text:
Available
Collection:
Tematic databases
Database:
BRISA/RedTESA
Main subject:
Crohn Disease
/
Adalimumab
/
Ustekinumab
/
Infliximab
Type of study:
Health technology assessment
Limits:
Humans
Language:
Spanish
Year:
2023
Document type:
Non-conventional
